TY - JOUR
T1 - Concurrent Control of Blood Glucose, Body Mass, and Blood Pressure in Patients With Type 2 Diabetes
T2 - An Analysis of Data From Electronic Medical Records
AU - McAdam-Marx, Carrie
AU - Bouchard, Jonathan
AU - Aagren, Mark
AU - Conner, Chris
AU - Brixner, Diana I.
N1 - Funding Information:
This study was funded in part through an unrestricted research grant made to the Pharmacotherapy Outcomes Research Center at the University of Utah by Novo Nordisk, Inc . Mr. Bouchard, Mr. Aagren, and Dr. Conner are employees of Novo Nordisk, Inc. Dr. Brixner has received consultancy funds from Novo Nordisk, Inc.
PY - 2011/1
Y1 - 2011/1
N2 - Objective: This cross-sectional study describes glycemic, body mass, and blood pressure (BP) control in patients with type 2 diabetes mellitus (T2DM) in an ambulatory care-based database of electronic medical records (EMRs). Methods: Patients aged ≥18 years with T2DM documented in 2008 and with glycosylated hemoglobin (HbA1c) value, body mass index (BMI), and BP charted within 90 days before or after T2DM documentation were identified using the General Electric Centricity EMR research database. Control of glycemia (controlled, <7.0%; uncontrolled, ≥7.0% [intermediate, 7.0%- <9.0%; poor, ≥9.0%]), body mass (nonobese, <30 kg/ m2; obese, ≥30 kg/m2 [intermediate, 30-<35 kg/m2; poor, ≥35 kg/m2]), and BP (controlled, <130/<80 mm Hg; uncontrolled, ≥130/≥80 mm Hg [intermediate, 130-<160/80-<100 mm Hg; poor, ≥160/≥100 mm Hg]) was identified, and patients were stratified by level of control individually and in combination. Comorbidities and antidiabetic and antihypertensive treatments prescribed in the year before the index date were identified in the EMR. Results: The mean (SD) age of the cohort (N = 49,560) was 60.9 (12.4) years; 51.5% were female. A minority had controlled glycemia (36.4%), body mass (30.2%), and/or BP (36.4%). Of those with controlled glycemia and body mass, 44.8% also had controlled BP, representing 5.5% of the overall study population. Conclusions: Despite the potential selection bias, a minority of patients in this cross-sectional study were at HbA1c, BP, or BMI goals, and even fewer gained control of all 3 of these risk factors. More intensive T2DM treatment with complementary efforts to manage body mass and BP is warranted in this population.
AB - Objective: This cross-sectional study describes glycemic, body mass, and blood pressure (BP) control in patients with type 2 diabetes mellitus (T2DM) in an ambulatory care-based database of electronic medical records (EMRs). Methods: Patients aged ≥18 years with T2DM documented in 2008 and with glycosylated hemoglobin (HbA1c) value, body mass index (BMI), and BP charted within 90 days before or after T2DM documentation were identified using the General Electric Centricity EMR research database. Control of glycemia (controlled, <7.0%; uncontrolled, ≥7.0% [intermediate, 7.0%- <9.0%; poor, ≥9.0%]), body mass (nonobese, <30 kg/ m2; obese, ≥30 kg/m2 [intermediate, 30-<35 kg/m2; poor, ≥35 kg/m2]), and BP (controlled, <130/<80 mm Hg; uncontrolled, ≥130/≥80 mm Hg [intermediate, 130-<160/80-<100 mm Hg; poor, ≥160/≥100 mm Hg]) was identified, and patients were stratified by level of control individually and in combination. Comorbidities and antidiabetic and antihypertensive treatments prescribed in the year before the index date were identified in the EMR. Results: The mean (SD) age of the cohort (N = 49,560) was 60.9 (12.4) years; 51.5% were female. A minority had controlled glycemia (36.4%), body mass (30.2%), and/or BP (36.4%). Of those with controlled glycemia and body mass, 44.8% also had controlled BP, representing 5.5% of the overall study population. Conclusions: Despite the potential selection bias, a minority of patients in this cross-sectional study were at HbA1c, BP, or BMI goals, and even fewer gained control of all 3 of these risk factors. More intensive T2DM treatment with complementary efforts to manage body mass and BP is warranted in this population.
KW - Dyslipidemia
KW - Glycemic control
KW - HbA1c
KW - Hypertension
KW - Obesity
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=79952528956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952528956&partnerID=8YFLogxK
U2 - 10.1016/j.clinthera.2011.01.018
DO - 10.1016/j.clinthera.2011.01.018
M3 - Article
C2 - 21397777
AN - SCOPUS:79952528956
SN - 0149-2918
VL - 33
SP - 110
EP - 120
JO - Clinical Therapeutics
JF - Clinical Therapeutics
IS - 1
ER -